Modernizing Opioid Treatment Access Act 2.0 of 2026

H.R.9790/S.4941, Modernizing Opioid Treatment Access Act, Entirety Monitor the following: H.R.2586, Reentry Act of 2025, Entirety Substance Use Disorder, Medicaid Coverage for MATs Medication-Assisted Treatment (MAT) delivery related issues Substance Use Disorders, Training related issues Telehealth for providing Medication-Assisted Treatment (MAT) Public Law 119-75, Consolidated Appropriations Act, 2026, Division B - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Proposed consolidation of block grants and SAMSHA S.4941, A bill to expand access to methadone through alternative care models using pharmacies, Entirety

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.

Issues related to opioid addiction recovery and drug treatment programs - no specific legislation. H.R. 5629, To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect. S.4941 - Modernizing Opioid Treatment Access Act 2.0 of 2026.

Client expense: Not reported · Firm income: $20,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Behavioral Health Issues related to behavioral health - no specific bill Childcare Issues related to childcare - no specific bill Gun Safety Issues related to gun safety - no specific bill Health Care Issues related to health care/universal access to quality, equitable, affordable coverage - no specific bill Issues related to mental and behavioral health care - no specific bill Issues related to Private Equity/Healthcare - no specific bill H.R. 2191, Physician Led and Rural Access to Quality Care Act Support of community water fluoridation - no specific bill Extend Premium Tax Credits - no specific bill Health Care Workforce Issues related to health care workforce shortages - no specific bill Issues related to the affordability of medical education and federal loan programs - no specific bill Issues related to scope of practice - no specific bill Issues related to the Department of Veterans Affairs Federal Supremacy Project - no specific bill Demographic data collection - no specific bill H.R. 929/S.266 the Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 3890/S. 2439, the Resident Physician Shortage Reduction Act H.R. 5283/S. 2759, the Healthcare Workforce Resilience Act H.R. 3164, the Ensuring Community Access to Pharmacist Services (ECAPS) Act H.R. 4002, the Patient Access to Higher Quality Health Care Act of 2025 HIV/AIDS Presidents Emergency Plan for AIDS Relief (PEPFAR) Immigration Issues related to Immigration - no specific bill H.R.1585/S.709 the Conrad State 30 and Physician Access Reauthorization Act Protecting Immigrant Families (PIF) Campaign H.R.1061/S.455 Protecting Sensitive Locations Act Infrastructure Issues related to broadband access - no specific bill Interoperability/ONC Issues related to interoperability and information blocking - no specific bill Maternal Health and Reproductive Health H.R. 3480 Health Coverage for IVF Act S. 2035 Protect IVF Act S.3743 - Supporting Healthy Moms and Infants Act Issues related to maternal health - no specific bill S. 141, The Connected Maternal Online Monitoring (MOM) Act Medical Education Issues related to the affordability of medical education - no specific bill Issues related to student loan forgiveness - no specific bill Support for physicians, residents and medical students - no specific bill Medicare/Medicaid H.R. 9693, the Patients First Act. H.R. 8163, the Provider Reimbursement Stability Act S. 1816/H.R. 3514, Improving Seniors Timely Access to Care Act of 2025 Budget neutrality rules in the Medicare Physician Fee Schedule - no specific bill H.R. 2757 Medicare Audiology Access Improvement Act of 2025 S. 575 the Improving Care and Access to Nurses Act H.R. 879 the Medicare Patient Access and Practice Stabilization Act H.R. 8163, the Provider Reimbursement Stability Act Issues related to Medicare physician payment - no specific bill Issues related to Medicare/Medicaid - no specific bill H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Issues related to Medicare Advantage - no specific bill H.R. 1, One Big Beautiful Bill Act H.R. 2757, Medicare Audiology Access Improvement Act S. 106/H.R. 539, the Chiropractic Medicare Coverage Modernization Act of 2025 Nutrition Issues related to nutrition and food security - no specific bill Issues related to SNAP funding - - no specific bill (including H.R.1) Opioids/ Substance Use Disorder MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 Issues related to opioids and substance use disorder - no specific bill Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill HR 4002, The Patient Access to Higher Quality Health Care Act Publications Open access to information based on publicly funded research - no specific bill Request for Information for NIH Plan to Enhance Public Access to the Results of NIH-Supported Research Issues related to scholarly and scientific publishing and public access - no specific bill Racial Justice/Health Equity Issues related to racial justice/health care equity - no specific bill Health disparities and protecting vulnerable populations - no specific bill Issues related to equitable policies around blood, tissue donations - no specific bill Surprise Billing H.R. 4710/S. 2420, the No Surprises Act Enforcement Act Issues related to surprise billing - no specific bill Issues related to the implementation of the No Surprises Act - no specific bill Telehealth S. 1261, the CONNECT for Health Act of 2025 H.R. 5081/S. 2709, the Telehealth Modernization Act of 2025 H.R. 1650, the Telehealth Expansion Act of 2025 Issues related to telehealth - no specific bill Issues related to telebehavioral health access - no specific bill Issues related to physician licensing - no specific bill Issues related to telehealth PHE flexibilities/waivers - no specific bill Tobacco Issues related to prohibiting sale of menthol cigarettes and flavored cigars - no specific bill Issues related to increasing awareness about lung cancer screening on cigarette packages - no specific bill Vaccines H.R.5448/S.2857 Protecting Free Vaccines Act of 2025 H.R.3701/S.3323 Family Vaccine Protection Act Issues related to vaccines - no specific bill Regulatory FDA's proposed rule to eliminate menthol cigarettes Issues related to Medicare physician payment Issues related to implementation of the No Surprises Act Issues related to telehealth Issues related to Medicare Advantage Star Rating Health Equity Index calculation HIPAA-related Reporting Requirements Involving the Change Healthcare Cyber Incident Marketplace Integrity and Affordability Proposed Rule (CMS-9884-P) Medicaid Program; Preserving Medicaid Funding for Vulnerable Populations-Closing a Health Care-Related Tax Loophole Proposed Rule (CMS-2448-P) Notice: Personal Responsibility and Work Opportunity Reconciliation Act of 1996 (PRWORA); Interpretation of Federal Public Benefit NIH RFI on Maximizing Research Funds by Limiting Allowable Publishing Costs File Code CMS-3481-P. Medicare and Medicaid Programs; Hospital Condition of Participation: Prohibiting Sex-Rejecting Procedures for Children File Code CMS-2451-P Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children OMB-2026-0034, Proposed Revisions to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards File Code CMS-2454-IFC. Medicaid Program; Community Engagement Requirement for Certain Individuals Docket No. HHS-OS-2026-0332; RIN 0991-ZA62 - Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making (91 Fed. Reg. 54724, Aug. 24, 2026) File Code CMS-1848-P. Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program Notice of Proposed Rulemaking, Fee for Certain H-1B Petitions, 91 Fed. Reg. 54817 (Aug. 25, 2026); DHS Docket No. USCIS-2026-0298; CIS No. 2861-26; RIN 1615-AD20 Medicaid Program; Amending the Indirect Hold Harmless Threshold of Health Care-Related Taxes, File Code: CMS-2452-P, RIN 0938-AV93, 91 Fed. Reg. 46562 (published July 23, 2026) File Code CMS-1848-P; Medicare Program; CY 2027 Payment Policies Under the Physician Payment Schedule and Other Changes to Part B Payment and Coverage Policies; (July 16, 2026). Accounting for E/M Resource Overlap Between Stand-Alone Visits and Global Periods File Code ACF-2026-0595-0001; Reducing Federal Burden for Head Start Programs

Opioids/ Substance Use Disorder MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act Issues related to opioids and substance use disorder - no specific bill

Client expense: $50,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE

Behavioral Health Issues related to behavioral health - no specific bill Childcare Issues related to childcare - no specific bill Health Care Issues related to health care/universal access to quality, equitable, affordable coverage - no specific bill Issues related to mental and behavioral health care - no specific bill Issues related to Private Equity/Healthcare - no specific bill H.R. 2191, Physician Led and Rural Access to Quality Care Act Support of community water fluoridation - no specific bill Extend Premium Tax Credits - no specific bill Health Care Workforce Issues related to health care workforce shortages - no specific bill Issues related to the affordability of medical education and federal loan programs - no specific bill Issues related to scope of practice - no specific bill Issues related to the Department of Veterans Affairs Federal Supremacy Project - no specific bill Demographic data collection - no specific bill H.R. 929/S.266 the Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 3890/S. 2439, the Resident Physician Shortage Reduction Act H.R. 5283/S. 2759, the Healthcare Workforce Resilience Act H.R. 3164, the Ensuring Community Access to Pharmacist Services (ECAPS) Act H.R. 4002, the Patient Access to Higher Quality Health Care Act of 2025 HIV/AIDS Presidents Emergency Plan for AIDS Relief (PEPFAR) Immigration Issues related to Immigration - no specific bill H.R.1585/S.709 the Conrad State 30 and Physician Access Reauthorization Act Protecting Immigrant Families (PIF) Campaign H.R.1061/S.455 Protecting Sensitive Locations Act Infrastructure Issues related to broadband access - no specific bill Interoperability/ONC Issues related to interoperability and information blocking - no specific bill Maternal Health and Reproductive Health H.R. 3480 Health Coverage for IVF Act S. 2035 Protect IVF Act S.3743 - Supporting Healthy Moms and Infants Act Issues related to maternal health - no specific bill S. 141, The Connected Maternal Online Monitoring (MOM) Act Medicare/Medicaid H.R. 9693, the Patients First Act. H.R. 8163, the Provider Reimbursement Stability Act S. 1816/H.R. 3514, Improving Seniors Timely Access to Care Act of 2025 Budget neutrality rules in the Medicare Physician Fee Schedule - no specific bill H.R. 2757 Medicare Audiology Access Improvement Act of 2025 S. 575 the Improving Care and Access to Nurses Act H.R. 879 the Medicare Patient Access and Practice Stabilization Act H.R. 8163, the Provider Reimbursement Stability Act Issues related to Medicare physician payment - no specific bill Issues related to Medicare/Medicaid - no specific bill H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Issues related to Medicare Advantage - no specific bill H.R. 1, One Big Beautiful Bill Act H.R. 2757, Medicare Audiology Access Improvement Act S. 106/H.R. 539, the Chiropractic Medicare Coverage Modernization Act of 2025 Nutrition Issues related to nutrition and food security - no specific bill Issues related to SNAP funding - - no specific bill (including H.R.1) Opioids/ Substance Use Disorder MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 Issues related to opioids and substance use disorder - no specific bill Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill HR 4002, The Patient Access to Higher Quality Health Care Act Racial Justice/Health Equity Issues related to racial justice/health care equity - no specific bill Health disparities and protecting vulnerable populations - no specific bill Issues related to equitable policies around blood, tissue donations - no specific bill Surprise Billing H.R. 4710/S. 2420, the No Surprises Act Enforcement Act Issues related to surprise billing - no specific bill Issues related to the implementation of the No Surprises Act - no specific bill Telehealth S. 1261, the CONNECT for Health Act of 2025 H.R. 5081/S. 2709, the Telehealth Modernization Act of 2025 H.R. 1650, the Telehealth Expansion Act of 2025 Issues related to telehealth - no specific bill Issues related to telebehavioral health access - no specific bill Issues related to physician licensing - no specific bill Issues related to telehealth PHE flexibilities/waivers - no specific bill Tobacco Issues related to prohibiting sale of menthol cigarettes and flavored cigars - no specific bill Issues related to increasing awareness about lung cancer screening on cigarette packages - no specific bill Vaccines H.R.5448/S.2857 Protecting Free Vaccines Act of 2025 H.R.3701/S.3323 Family Vaccine Protection Act Issues related to vaccines - no specific bill Regulatory FDA's proposed rule to eliminate menthol cigarettes Issues related to Medicare physician payment Issues related to implementation of the No Surprises Act Issues related to telehealth Issues related to Medicare Advantage Star Rating Health Equity Index calculation HIPAA-related Reporting Requirements Involving the Change Healthcare Cyber Incident Marketplace Integrity and Affordability Proposed Rule (CMS-9884-P) Medicaid Program; Preserving Medicaid Funding for Vulnerable Populations-Closing a Health Care-Related Tax Loophole Proposed Rule (CMS-2448-P) Notice: Personal Responsibility and Work Opportunity Reconciliation Act of 1996 (PRWORA); Interpretation of Federal Public Benefit NIH RFI on Maximizing Research Funds by Limiting Allowable Publishing Costs File Code CMS-3481-P. Medicare and Medicaid Programs; Hospital Condition of Participation: Prohibiting Sex-Rejecting Procedures for Children File Code CMS-2451-P Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children File Code CMS-2454-IFC. Medicaid Program; Community Engagement Requirement for Certain Individuals Docket No. HHS-OS-2026-0332; RIN 0991-ZA62 - Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making (91 Fed. Reg. 54724, Aug. 24, 2026) File Code CMS-1848-P. Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program Notice of Proposed Rulemaking, Fee for Certain H-1B Petitions, 91 Fed. Reg. 54817 (Aug. 25, 2026); DHS Docket No. USCIS-2026-0298; CIS No. 2861-26; RIN 1615-AD20 Medicaid Program; Amending the Indirect Hold Harmless Threshold of Health Care-Related Taxes, File Code: CMS-2452-P, RIN 0938-AV93, 91 Fed. Reg. 46562 (published July 23, 2026) File Code CMS-1848-P; Medicare Program; CY 2027 Payment Policies Under the Physician Payment Schedule and Other Changes to Part B Payment and Coverage Policies; (July 16, 2026). Accounting for E/M Resource Overlap Between Stand-Alone Visits and Global Periods File Code ACF-2026-0595-0001; Reducing Federal Burden for Head Start Programs

-Expand access to medication-assisted treatment -Drug Enforcement Agency (DEA) - rules for prescribing controlled medications via telemedicine -Contingency Management -Modernizing Opioid Treatment Access Act (MOTAA) 2.0 (S. 4941) -H.R. 5629 - bill to nullify SAMHSA rule -Teleprescribing for controlled substances -SUD treatment facility fraud

Client expense: $54,762 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of, White House Office

H.R.4484/S.2356, ADAPT Act H.Res.697, Supporting September as National Suicide Prevention Month Budget Reconciliation bill Alleviating Barriers for Caregivers Act Response to FDA proposed industry guidance on AI-enabled device Budget Reconciliation H. R. 912/S. 1007, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 929/S. 266, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 957, Parity Enforcement Act of 2025 H.R 2509/ S. 931, COMPLETE Care Act H.R. 2630, Youth Suicide Prevention Research Act H.R. 3266/ S. 1673, Mental Health Infrastructure Improvement Act H.R.3505/ S. 5558, Barriers to Suicide Act of 2025 H.R. 3624/S.1924, Improving Mental Health Access for Students Act H.R. 5178 /S. 721 Sickle Cell Disease Comprehensive Care Act H.R 4619/S.4076, Medicare Mental Health Inpatient Equity Act H.R. 4744, Community Mental Wellness and Resilience Act of 2025 H.R. 4745/ S.2410, The Medicaid Bump Act H.R. 5145, Bipartisan Premium Tax Credit Extension Act H.R. 5482, Prevent Youth Suicide Act H.R.5629, Medications for the Treatment of Opioid Use Disorder H.R.5630, to Require Additional Information in State Plans for SUPTRS Block Grant H.R. 5706, Mental Health Emergency Responder Act H.R. 6396, Kid PROOF Act of 2025 H.R. 6601, CARE for First Responders Act S.683/H.R.7324, More Behavioral Health Providers Act of 2025 S. 1062, Suicide Prevention Act H.R. 2904/S. 1448 Pursuing Equity in Mental Health Act Rural Behavioral Health Improvement Act (H.R. 5217) Therapeutic Fraud Prevention Act (H.R. 3243 / S. 1663) H.R. 12/S. 2150 Womens Health Protection Act of 2025 S.2826/H.R.5434, 988 LGBTQ+ Youth Access Act S. 3431, Improving Measurements for Loneliness and Isolation Act of 2025 Black women and girls mental health Senior Chatbot Protection Act (S. 5117) Docs Not AI Act (TBD)H.R 2587/S.1266 - Youth Mental Health Research Act Coalition Letter to Protect LGBTQ+ dedicated line to 988 S.2826/H.R.5434, 988 LGBTQ+ Youth Access Act H.R. 138 / S. 1565 Lowering Costs for Caregivers Act H.R.7092/S.4061, Raising Awareness for Youth Suicide Prevention Act (RAYS) Act H.R. 7875, Providing Opportunities for Individuals in Need of Treatment and Support Act (POINTS Act) H.R. 7985 CHATBOT Act H.R.8122/ S.4640, 9-8-8 Connect Act H.R.8124, Stabilization to Prevent (STOP) Suicide Act H.R.8201, Require FQHCs to Provide Behavioral and Mental Health and Substance Use Disorder Services H.R.8487/S.3402, Ensuring Excellence in Mental Health Act H.R.9257/S.4754, The Primary and Behavioral Health Care Access Act H.R.9389, Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 H.R.9551, Mental Health Parity Enforcement and Funding Act H.R. 9693, the Patients First Act of 2026 H.R. 9790/S. 4941, Modernizing Opioid Treatment Access Act 2.0 (MOTAA 2.0) H.R. 9990/S. 5120, Increasing Mental Health Options (IMHO) Act H.R.10280, 9-8-8 Implementation Act of 2026 S.4076/H.R.4619, To End the 190-day Lifetime Limit on Inpatient Psychiatric Care Under Medicare S.5269, Pay PCPs Act of 2026 Access to evidence-based behavioral treatments for substance use disorders Psychedelic Therapies - Training and Policy CMS ACCESS Model FDA Digital Therapeutics CDC Youth Mental Health

Issues related to opioid addiction recovery and drug treatment programs - no specific legislation. Public Law No: 119-21, One Big Beautiful Bill Act. H.R. 5629, To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect. S.4941 - Modernizing Opioid Treatment Access Act 2.0 of 2026.

Client expense: Not reported · Firm income: $20,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES

Opioids/ Substance Use Disorder MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act Issues related to opioids and substance use disorder - no specific bill

Client expense: $50,000 · Firm income: Not reported

Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, SENATE

Behavioral Health Issues related to behavioral health - no specific bill Childcare Issues related to childcare - no specific bill Health Care Issues related to health care/universal access to quality, equitable, affordable coverage - no specific bill Issues related to mental and behavioral health care - no specific bill Issues related to Private Equity/Healthcare - no specific bill H.R. 2191, Physician Led and Rural Access to Quality Care Act Support of community water fluoridation - no specific bill Extend Premium Tax Credits - no specific bill Health Care Workforce Issues related to health care workforce shortages - no specific bill Issues related to the affordability of medical education and federal loan programs - no specific bill Issues related to scope of practice - no specific bill Issues related to the Department of Veterans Affairs Federal Supremacy Project - no specific bill Demographic data collection - no specific bill H.R. 929/S.266 the Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 3890/S. 2439, the Resident Physician Shortage Reduction Act H.R. 5283/S. 2759, the Healthcare Workforce Resilience Act H.R. 3164, the Ensuring Community Access to Pharmacist Services (ECAPS) Act H.R. 4002, the Patient Access to Higher Quality Health Care Act of 2025 HIV/AIDS Presidents Emergency Plan for AIDS Relief (PEPFAR) Immigration Issues related to Immigration - no specific bill H.R.1585/S.709 the Conrad State 30 and Physician Access Reauthorization Act Protecting Immigrant Families (PIF) Campaign H.R.1061/S.455 Protecting Sensitive Locations Act Infrastructure Issues related to broadband access - no specific bill Interoperability/ONC Issues related to interoperability and information blocking - no specific bill Maternal Health and Reproductive Health H.R. 3480 Health Coverage for IVF Act S. 2035 Protect IVF Act S.3743 - Supporting Healthy Moms and Infants Act Issues related to maternal health - no specific bill S. 141, The Connected Maternal Online Monitoring (MOM) Act Medicare/Medicaid H.R. 8163, the Provider Reimbursement Stability Act S. 1816/H.R. 3514, Improving Seniors Timely Access to Care Act of 2025 Budget neutrality rules in the Medicare Physician Fee Schedule - no specific bill H.R. 2757 Medicare Audiology Access Improvement Act of 2025 S. 575 the Improving Care and Access to Nurses Act H.R. 879 the Medicare Patient Access and Practice Stabilization Act H.R. 8163, the Provider Reimbursement Stability Act Issues related to Medicare physician payment - no specific bill Issues related to Medicare/Medicaid - no specific bill H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Issues related to Medicare Advantage - no specific bill H.R. 1, One Big Beautiful Bill Act H.R. 2757, Medicare Audiology Access Improvement Act S. 106/H.R. 539, the Chiropractic Medicare Coverage Modernization Act of 2025 Nutrition Issues related to nutrition and food security - no specific bill Issues related to SNAP funding - - no specific bill (including H.R.1) Opioids/ Substance Use Disorder MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 Issues related to opioids and substance use disorder - no specific bill Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill HR 4002, The Patient Access to Higher Quality Health Care Act Racial Justice/Health Equity Issues related to racial justice/health care equity - no specific bill Health disparities and protecting vulnerable populations - no specific bill Issues related to equitable policies around blood, tissue donations - no specific bill Surprise Billing H.R. 4710/S. 2420, the No Surprises Act Enforcement Act Issues related to surprise billing - no specific bill Issues related to the implementation of the No Surprises Act - no specific bill Telehealth S. 1261, the CONNECT for Health Act of 2025 H.R. 5081/S. 2709, the Telehealth Modernization Act of 2025 H.R. 1650, the Telehealth Expansion Act of 2025 Issues related to telehealth - no specific bill Issues related to telebehavioral health access - no specific bill Issues related to physician licensing - no specific bill Issues related to telehealth PHE flexibilities/waivers - no specific bill Tobacco Issues related to prohibiting sale of menthol cigarettes and flavored cigars - no specific bill Issues related to increasing awareness about lung cancer screening on cigarette packages - no specific bill Vaccines H.R.5448/S.2857 Protecting Free Vaccines Act of 2025 H.R.3701/S.3323 Family Vaccine Protection Act Issues related to vaccines - no specific bill Regulatory FDA's proposed rule to eliminate menthol cigarettes Issues related to Medicare physician payment Issues related to implementation of the No Surprises Act Issues related to telehealth Issues related to Medicare Advantage Star Rating Health Equity Index calculation HIPAA-related Reporting Requirements Involving the Change Healthcare Cyber Incident Marketplace Integrity and Affordability Proposed Rule (CMS-9884-P) Medicaid Program; Preserving Medicaid Funding for Vulnerable Populations-Closing a Health Care-Related Tax Loophole Proposed Rule (CMS-2448-P) Notice: Personal Responsibility and Work Opportunity Reconciliation Act of 1996 (PRWORA); Interpretation of Federal Public Benefit NIH RFI on Maximizing Research Funds by Limiting Allowable Publishing Costs File Code CMS-3481-P. Medicare and Medicaid Programs; Hospital Condition of Participation: Prohibiting Sex-Rejecting Procedures for Children File Code CMS-2451-P Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children

Behavioral Health Issues related to behavioral health - no specific bill Childcare Issues related to childcare - no specific bill Gun Safety Issues related to gun safety - no specific bill Health Care Issues related to health care/universal access to quality, equitable, affordable coverage - no specific bill Issues related to mental and behavioral health care - no specific bill Issues related to Private Equity/Healthcare - no specific bill H.R. 2191, Physician Led and Rural Access to Quality Care Act Support of community water fluoridation - no specific bill Extend Premium Tax Credits - no specific bill Health Care Workforce Issues related to health care workforce shortages - no specific bill Issues related to the affordability of medical education and federal loan programs - no specific bill Issues related to scope of practice - no specific bill Issues related to the Department of Veterans Affairs Federal Supremacy Project - no specific bill Demographic data collection - no specific bill H.R. 929/S.266 the Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 3890/S. 2439, the Resident Physician Shortage Reduction Act H.R. 5283/S. 2759, the Healthcare Workforce Resilience Act H.R. 3164, the Ensuring Community Access to Pharmacist Services (ECAPS) Act H.R. 4002, the Patient Access to Higher Quality Health Care Act of 2025 HIV/AIDS Presidents Emergency Plan for AIDS Relief (PEPFAR) Immigration Issues related to Immigration - no specific bill H.R.1585/S.709 the Conrad State 30 and Physician Access Reauthorization Act Protecting Immigrant Families (PIF) Campaign H.R.1061/S.455 Protecting Sensitive Locations Act Infrastructure Issues related to broadband access - no specific bill Interoperability/ONC Issues related to interoperability and information blocking - no specific bill Maternal Health and Reproductive Health H.R. 3480 Health Coverage for IVF Act S. 2035 Protect IVF Act S.3743 - Supporting Healthy Moms and Infants Act Issues related to maternal health - no specific bill S. 141, The Connected Maternal Online Monitoring (MOM) Act Medical Education Issues related to the affordability of medical education - no specific bill Issues related to student loan forgiveness - no specific bill Support for physicians, residents and medical students - no specific bill Medicare/Medicaid H.R. 8163, the Provider Reimbursement Stability Act S. 1816/H.R. 3514, Improving Seniors Timely Access to Care Act of 2025 Budget neutrality rules in the Medicare Physician Fee Schedule - no specific bill H.R. 2757 Medicare Audiology Access Improvement Act of 2025 S. 575 the Improving Care and Access to Nurses Act H.R. 879 the Medicare Patient Access and Practice Stabilization Act H.R. 8163, the Provider Reimbursement Stability Act Issues related to Medicare physician payment - no specific bill Issues related to Medicare/Medicaid - no specific bill H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Issues related to Medicare Advantage - no specific bill H.R. 1, One Big Beautiful Bill Act H.R. 2757, Medicare Audiology Access Improvement Act S. 106/H.R. 539, the Chiropractic Medicare Coverage Modernization Act of 2025 Nutrition Issues related to nutrition and food security - no specific bill Issues related to SNAP funding - - no specific bill (including H.R.1) Opioids/ Substance Use Disorder MATE ACT Adds New Education Mandate for 8 Hours of Continuing Education on Opioid Treatment H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act S.4941 Modernizing Opioid Treatment Access Act 2.0 of 2026 Issues related to opioids and substance use disorder - no specific bill Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill HR 4002, The Patient Access to Higher Quality Health Care Act Publications Open access to information based on publicly funded research - no specific bill Request for Information for NIH Plan to Enhance Public Access to the Results of NIH-Supported Research Issues related to scholarly and scientific publishing and public access - no specific bill Racial Justice/Health Equity Issues related to racial justice/health care equity - no specific bill Health disparities and protecting vulnerable populations - no specific bill Issues related to equitable policies around blood, tissue donations - no specific bill Surprise Billing H.R. 4710/S. 2420, the No Surprises Act Enforcement Act Issues related to surprise billing - no specific bill Issues related to the implementation of the No Surprises Act - no specific bill Telehealth S. 1261, the CONNECT for Health Act of 2025 H.R. 5081/S. 2709, the Telehealth Modernization Act of 2025 H.R. 1650, the Telehealth Expansion Act of 2025 Issues related to telehealth - no specific bill Issues related to telebehavioral health access - no specific bill Issues related to physician licensing - no specific bill Issues related to telehealth PHE flexibilities/waivers - no specific bill Tobacco Issues related to prohibiting sale of menthol cigarettes and flavored cigars - no specific bill Issues related to increasing awareness about lung cancer screening on cigarette packages - no specific bill Vaccines H.R.5448/S.2857 Protecting Free Vaccines Act of 2025 H.R.3701/S.3323 Family Vaccine Protection Act Issues related to vaccines - no specific bill Regulatory FDA's proposed rule to eliminate menthol cigarettes Issues related to Medicare physician payment Issues related to implementation of the No Surprises Act Issues related to telehealth Issues related to Medicare Advantage Star Rating Health Equity Index calculation HIPAA-related Reporting Requirements Involving the Change Healthcare Cyber Incident Marketplace Integrity and Affordability Proposed Rule (CMS-9884-P) Medicaid Program; Preserving Medicaid Funding for Vulnerable Populations-Closing a Health Care-Related Tax Loophole Proposed Rule (CMS-2448-P) Notice: Personal Responsibility and Work Opportunity Reconciliation Act of 1996 (PRWORA); Interpretation of Federal Public Benefit NIH RFI on Maximizing Research Funds by Limiting Allowable Publishing Costs File Code CMS-3481-P. Medicare and Medicaid Programs; Hospital Condition of Participation: Prohibiting Sex-Rejecting Procedures for Children File Code CMS-2451-P Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children OMB-2026-0034, Proposed Revisions to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards

-Expand access to medication-assisted treatment -Drug Enforcement Agency (DEA) - rules for prescribing controlled medications via telemedicine -Contingency Management -Modernizing Opioid Treatment Access Act (MOTAA) 2.0 (S. 4941) -H.R. 5629 - bill to nullify SAMHSA rule

Client expense: $69,462 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of, White House Office

Modernizing Opioid Treatment Access Act, Entirety Monitor the following: H.R.2586, Reentry Act of 2025, Entirety Substance Use Disorder, Medicaid Coverage for MATs Medication-Assisted Treatment (MAT) delivery related issues Substance Use Disorders, Training related issues Telehealth for providing Medication-Assisted Treatment (MAT) Public Law 119-75, Consolidated Appropriations Act, 2026, Division B - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Proposed consolidation of block grants and SAMSHA S.4941, A bill to expand access to methadone through alternative care models using pharmacies, Entirety

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Regulation regarding opioids, regulation of fentanyl and methadone access related issues Modernizing Opioid Treatment Access Act, Entirety Monitor the following: H.R.9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, Proposed consolidation of block grants and SAMSHA S.3522, No Red Tape For Addiction Treatment Act, Entirety H.R.5629, To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect, Entirety H.R.2586, Reentry Act of 2025, Entirety Substance Use Disorder, Medicaid Coverage for MATs Medication-Assisted Treatment (MAT) delivery related issues Substance Use Disorders, Training related issues Telehealth for providing Medication-Assisted Treatment (MAT) Public Law 119-75, Consolidated Appropriations Act, 2026, Division B - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Proposed consolidation of block grants and SAMSHA S.4941, A bill to expand access to methadone through alternative care models using pharmacies, Entirety

Client expense: Not reported · Firm income: $20,000

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Client expense: $40,000 · Firm income: Not reported

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Client expense: $40,000 · Firm income: Not reported

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Client expense: $40,000 · Firm income: Not reported

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Client expense: $40,000 · Firm income: Not reported

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Client expense: $40,000 · Firm income: Not reported

Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration

Client expense: $40,000 · Firm income: Not reported